Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer
A phase 2 trial of Progestins in Endometrial cancer, run by Chang Gung Memorial Hospital, with a status the registry has not verified recently.
Overview
Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer is a phase 2 interventional study registered as NCT02990728 by Chang Gung Memorial Hospital, with 120 participants planned, started 2016-03 and due to reach its primary completion in 2018-03. Interventions recorded: Metformin, Mirena®. Conditions recorded: Endometrial Cancer.
Linked to the drug Progestins because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTreatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer and the tag pipeline.
- TrialValue of LNG-IUS as Fertility-preserving Treatment of EAH and EC
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer and the tag pipeline.
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Shares Endometrial cancer and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer and the tag pipeline.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Endometrial cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shares Endometrial cancer and the tag pipeline.
- TrialA Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Shares Endometrial cancer and the tag pipeline.